Zimmer Biomet Beats Q4 Estimates with 11% Revenue Growth, Flags Tariff Risks
Zimmer Biomet reported Q4 adjusted EPS of $2.42, beating estimates by $0.04, and revenue rose 11% year-over-year to $2.2 billion. Management issued 2026 guidance of $8.30–$8.45 adjusted EPS and projected free cash flow growth of 8–10%, while warning that tariffs could pressure margins.
1. Q4 Earnings Beat Estimates
Zimmer Biomet reported Q4 adjusted EPS of $2.42, $0.04 above consensus, on revenue of $2.2 billion, up 11% year-over-year, driven by strong demand for orthopedic implants and joint replacement systems.
2. 2026 Guidance and Free Cash Flow Outlook
Management issued full-year 2026 adjusted EPS guidance between $8.30 and $8.45 and forecast free cash flow growth of 8% to 10%, reflecting confidence in ongoing sales momentum and utilization trends in the United States.
3. Tariff Headwinds and Margin Concerns
The company warned that U.S. and imported component tariffs could pressure gross margins and EPS growth, prompting a conservative tone in its guidance as cost pressures persist.